Study design and rationale for Optimal aNtiplatelet pharmacotherapy guided by bedSIDE genetic or functional TESTing in elective percutaneous coronary intervention patients (ONSIDE TEST): a prospective, open-label, randomised parallel-group multicentre trial (NCT01930773) - Kołtowski, Łukasz; Aradi, Daniel; Huczek, Zenon; Tomaniak, Mariusz; Sibbing, Dirk; Filipiak, Krzysztof J; Kochman, Janusz; Balsam, Paweł; Opolski, Grzegorz (Kardiologia polska, 2016)
Keywords: Adolescent; Adult; Aged; Cytochrome P-450 CYP2C19 - genetics; Humans; Middle Aged; Myocardial Infarction - drug therapy; Myocardial Infarction - etiology; Myocardial Infarction - metabolism; Myocardial Infarction - prevention & control; Percutaneous Coronary Intervention - adverse effects; Pharmacogenomic Testing; Pharmacogenomic Variants; Platelet Aggregation Inhibitors - metabolism; Platelet Aggregation Inhibitors - therapeutic use; Platelet Function Tests; Prasugrel Hydrochloride - metabolism; Prasugrel Hydrochloride - therapeutic use; Prospective Studies; Research Design; Ticlopidine - analogs & derivatives; Ticlopidine - metabolism; Ticlopidine - therapeutic use; Young Adult; clopidogrel; prasugrel; high platelet reactivity; antiplatelet therapy; CYP2C192 allele polymorphism; percutaneous coronary interventions; bedside testing; stable coronary artery disease